Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404061 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| Bromide SCHEMBL14778654 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL1403807 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL12014339 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL1403881 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL12014344 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL4027543 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL12014335 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL12014338 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD | |
| SCHEMBL1404044 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1KEAP1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4313170-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212838-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2017198756-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-23 | — | — | WO | claimed |
| EP-3246028-A1 | QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-11-22 | — | — | EP | claimed |
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | claimed |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | claimed |
| US-8637531-B2 | Pyrido(3,2-d)pyridmidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-01-28 | — | — | US | claimed |
| CN-101835820-B | Process for production of polyester-containing flexible polyurethane foam, and catalyst composition for use in the process | TOSOH CORP | 2012-11-21 | — | — | CN | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | KDM4E 4489/4885ALDH1A1 3862/4885KEAP1 1979/4885 |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDM4E 291/4885ALDH1A1 487/4885KEAP1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.